Doctiplus - We are allways here!
Dementia & Alzheimer's
Weekly Report
- 7 new clinical trials registered across 4 countries.
- 954 trials actively recruiting patients worldwide.
- Notable trial: A Prospective Cohort Study of Multimodal Biomarkers and Progression From Mild Cognitive Impairment to Dementia (600 patients).
- 385 new research papers published.
- Drug safety: Most reported effect across tracked medications (donepezil, memantine, rivastigmine, galantamine, lecanemab) was Death.
- No active drug recalls for tracked medications this week.
The week in numbers
Trials by country
Trials by phase
New clinical trials registered this week for Dementia & Alzheimer's. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.
This week's new registrations
7 trials registered for Dementia & Alzheimer's. Each links to its full record on ClinicalTrials.gov.
| # | Trial ↓ | Phase ↕ | Status ↕ | Enrollment ↕ | Country ↕ |
|---|---|---|---|---|---|
| 01 | Study on Clinical Characteristics of Patients With Probable Alzheimer's Dementia Stratified by Blood Biomarkers Dementia & Alzheimer's · Tianjin Anding Hospital (NCT07875998) | Other | Recruiting | 200 | China |
| 02 | Flutemetamol F 18 Injection Formulation Comparison Dementia & Alzheimer's · GE Healthcare (NCT07873463) | Phase 2 | Not Yet Recruiting | 20 | United States |
| 03 | Feasibility Study of a Co-Designed Gamified Medical Yoga App for Home-Based Cancer Rehabilitation Dementia & Alzheimer's · Linkoeping University (NCT07872956) | Other | Recruiting | 10 | Sweden |
| 04 | HomeCare Medication Management for People With Dementia Dementia & Alzheimer's · HiDO Technologies (NCT07872072) | Other | Not Yet Recruiting | 120 | United States |
| 05 | Tau Pathology in the Brain After Hip or Knee Replacement Surgery Dementia & Alzheimer's · Uppsala University Hospital (NCT07871487) | Other | Recruiting | 30 | Sweden |
| 06 | Functionalized Point of Care and 3D Printed Dental Aligners as Devices for Early Detection of Neurodegenerative Diseases Dementia & Alzheimer's · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (NCT07870070) | Other | Active Not Recruiting | 256 | Italy |
| 07 | A Prospective Cohort Study of Multimodal Biomarkers and Progression From Mild Cognitive Impairment to Dementia Dementia & Alzheimer's · Xuanwu Hospital, Beijing (NCT07876570) | Other | Recruiting | 600 | China |
Adverse event reports
Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Dementia & Alzheimer's. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.
Reports by drug
| Drug | Top effect | Count |
|---|---|---|
| donepezil | Death | 208 |
| memantine | Death | 129 |
| rivastigmine | Death | 292 |
| galantamine | Fall | 32 |
| lecanemab | Amyloid Related Imaging Abnormality-oedema/effusion | 202 |
Recalls & safety notices
FDA drug recall notices for medications related to Dementia & Alzheimer's. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.
No active drug recalls for tracked medications this period.
Published research
Recently published peer-reviewed studies related to Dementia & Alzheimer's, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.
| # | Study | Journal | Date | Source |
|---|---|---|---|---|
| 01 |
Supporting Social Engagement in Long-Term Care Through Paired Socially Assistive Robot-Virtual Reality Activities for Older Adults with Cognitive Impairment and Apathy.
View abstractINTRODUCTION: Older adults living in long-term care settings, particularly those with cognitive impairment and apathy, frequently experience reduced social engagement. Socially assistive robots and virtual reality systems may help support engagement, but little is known about whether they can sustain engagement during real-world deployment while also facilitating interaction between older adults. This study examined whether socially structured socially assistive robot-virtual reality (SAR-VR) systems could sustain engagement and support human-human interaction during repeated use in long-term care settings. METHODS: This analysis focused on the SAR-VR intervention arm of a larger eight-week study and included 60 older adults with cognitive impairment from 23 long-term care sites. Participants were exposed to two SAR-VR systems featuring different robot embodiments (dog-like and humanoid), roles, and activities. Across 756 repeated intervention sessions, engagement was observationally assessed using observed ratings of attention, activity attitude, robot attitude, and conversational targeting. RESULTS: Sustained attention and activity attitudes remained consistently positive across both SAR-VR systems over repeated exposure. Peer-to-peer and research-staff directed speech occurred across both systems. While robot-directed speech was more common in the dog-like condition, partner-directed communication remained stable, indicating that increased human-robot interaction did not occur at the expense of human-human interaction. Baseline cognitive functioning was associated with attentional engagement but not with attitudinal evaluations. Baseline technology acceptance did not strongly predict post-interaction impressions. Participants who anthropomorphized the robots at baseline demonstrated more positive engagement during sessions. DISCUSSION: These findings suggest that socially structured SAR-VR systems can sustain meaningful engagement while preserving peer interaction in naturalistic dementia care. The results also support the feasibility of designing SAR-VR activities around shared goals and coordinated actions to promote reciprocal human engagement, while recognizing that the study design does not allow definitive conclusions about clinical efficacy or the effects of specific robot features. |
Clinical interventions in aging | 2026 | PubMed |
| 02 |
Associations of mild behavioral impairment and white matter hyperintensity patterns.
View abstractINTRODUCTION: It is unclear whether cerebrovascular and white matter changes contribute to mild behavioral impairment (MBI). White matter hyperintensities (WMHs) represent a prominent pathology for research due to association with cognitive decline. We investigated associations between MBI measures and WMH volume and spatial distribution. METHODS: We analyzed 1273 individuals with normal cognition or mild cognitive impairment. General linear models and voxel-wise analyses were employed to examine WMHs in terms of volume and spatial distribution. RESULTS: Greater WMH volume was associated with higher MBI total score and MBI status in participants with normal cognition and mild cognitive impairment. Voxel-wise analysis revealed a significant cluster in the left inferior longitudinal fasciculus associated with higher MBI total score. DISCUSSION: Our findings suggest a contribution of WMH volume and spatial distribution to persistent later-life behavioral symptoms. WMHs, especially in the left inferior longitudinal fasciculus, may serve as a neuroimaging marker of behavioral symptoms. |
Alzheimer's & dementia (Amsterdam, Netherlands) | 2026 Oct-Dec | PubMed |
| 03 |
Evidence for Reduced Somatic T-Cell Receptor Sequence Diversity Profiles Among Midwestern Amish in an Aging Cohort Study.
View abstractBACKGROUND: The causes of late onset Alzheimer disease (LOAD) are not known but several recent lines of evidence implicate the adaptive immune system. OBJECTIVE: To characterize the adaptive immune system among Midwestern Amish participating in longitudinal studies of aging. METHODS: We immunosequenced the T-cell receptor (TCR) beta chain from genomic DNA of 72 participants, including those with clinically diagnosed LOAD (n = 6), mild cognitive impairment (MCI; n = 16), cognitive impairment but not AD (n = 3), and 35 cognitively unaffected. For a subset of participants, LOAD pathogenesis plasma biomarkers were available. RESULTS: TCR sequence diversity measured as Simpson's clonality was lower among LOAD+MCI compared with non-LOAD, but these differences were not independent of age. Relatively few clonotypes (exact nucleotide sequences) were shared across participants; of those few shared include the Epstein Barr virus associated clonotype. HLA-A*03:01 and several HLA-DRB1 alleles were under-represented among LOAD+MCI participants compared with cognitively unaffected participants, but these associations were no longer significant in adjusted analyses. Among LOAD+MCI participants, increased p-tau181 was nominally associated with decreased TCR sequence diversity, and the nominal association was independent of age; however, this association did not remain statistically significant after strict correction for multiple testing and the limited sample size precluded formal tests of heterogeneity. RESULTS: In this limited Midwestern Amish sample, the preliminary TCR diversity trends are consistent with the involvement of the adaptive immune system in LOAD. |
Annals of human genetics | 2026 Oct 18 | PubMed |
| 04 |
Potential Mechanisms of N-Methyltyramine in Multitarget Regulation of Mental Disorders via the GPCR-cAMP Pathway.
View abstractN-Methyltyramine (NMT) is a tyramine derivative widely distributed in citrus plants and the traditional Chinese medicine Zhishi. Pharmacological studies have confirmed that NMT directly binds to the dopamine D₂ receptor (DRD2; Ki = 31.3µM), inhibits forskolin-induced cAMP accumulation (EC₅₀ ≈ 4µM, Emax = 89%), and dose-dependently antagonizes quinpirole-mediated β-arrestin2 recruitment, exhibiting G protein-biased agonistic properties. Meanwhile, NMT activates the human trace amine-associated receptor 1 (hTAAR1; EC₅₀ ≈ 2µM) to increase cAMP, possesses α₂-adrenergic receptor antagonistic activity (IC₅₀ = 5.53µM), and exhibits blood-brain barrier permeability (logPe = -5.16cm/s). Based on these multi-target receptor profiles, NMT may participate in the regulation of central monoaminergic neurotransmission via the GPCR-cAMP signaling axis, providing a new multi-target lead compound direction for research on neurological disorders such as Alzheimer's disease, depression, and drug addiction. Notably, evidence for direct activation of β₂-adrenergic receptors by NMT remains insufficient, and its therapeutic effects and downstream signal integration mechanisms require NMT-specific experimental validation. |
Brain research bulletin | 2026 Oct 17 | PubMed |
| 05 |
Dysregulated Metal Homeostasis in Alzheimer's Disease: From Pathological Modulators to Therapeutic Targets.
View abstractThe "metal ion hypothesis" of Alzheimer's disease (AD) has gained widespread acceptance, but translating this understanding into effective therapies remains elusive. This likely stems from a simplistic understanding of metal homeostasis as merely a matter of "excess and deficiency." This article reviews the context-dependent roles of iron, copper, zinc, aluminum, and manganese in the pathogenesis of AD, with a particular focus on their bidirectional interactions with classic AD pathology (the ferroptosis hypothesis is relatively mature, while emerging hypotheses such as cuproptosis have not been fully elucidated). Metal homeostasis dysregulation can directly promote β-amyloid aggregation, tau hyperphosphorylation, oxidative stress, neuroinflammation, and regulated cell death. Conversely, these pathological processes can also alter the binding, storage, transport, and subcellular distribution of metal ions. Dysregulated metal ions function as "context-dependent" modulators of pathological processes. Their functional effects depend on metal species, concentration, binding state, subcellular compartment, and disease stage. Metal homeostasis dysregulation associated with AD may essentially reflect a redistribution between physiological and pathological pools. Ideal interventions should selectively neutralize pathological metal pools while preserving or restoring essential metal-dependent neuronal functions. By integrating the latest advances in the field of metal-targeted therapies (chelators, metabolic modulators, biomarkers, metal imaging, and gene editing), we emphasize that future treatments should shift from nonspecific metal clearance toward precise metal regulation and precision medicine. |
Pharmacological research | 2026 Oct 17 | PubMed |
| 06 |
A natural neuronal receptor-derived MRI probe targets β-amyloid oligomers for the diagnosis of Alzheimer's disease.
View abstractEarly-to-mid detection of Alzheimer's disease (AD) remains challenging because clinically used amyloid positron emission tomography (PET) probes primarily visualize fibrillar β-amyloid (Aβ) deposits and require radioactive isotopes. Magnetic resonance imaging (MRI) offers a radiation-free alternative, but its application in molecular AD diagnosis is limited by insufficient blood-brain barrier (BBB) penetration and poor specificity toward early-to-mid Aβ species. Here, we developed a BBB-crossing liposomal MRI probe, Lipo@D1D2-Gd, by integrating a natural Aβ oligomer-binding receptor domain with a gadolinium chelator. The extracellular D1D2 domains of human leukocyte immunoglobulin-like receptor B2 (LilrB2), a neuronal receptor that recognizes neurotoxic Aβ oligomers, were recombinantly produced and bioorthogonally conjugated with a gadolinium chelator. The resulting D1D2-Gd retained its Aβ-binding capability and MRI contrast activity. To enable brain delivery, D1D2-Gd was encapsulated within maltose-functionalized PEGylated liposomes designed to facilitate BBB transport. After intravenous administration to 4-month-old 5xFAD mice, Lipo@D1D2-Gd crossed the BBB, accumulated in Aβ-rich brain regions, and generated MRI contrast enhancement that differentiated 5xFAD mice from wild-type controls. Systemic safety evaluation showed no obvious hematological, biochemical, or histological toxicity. This study establishes a receptor-derived, BBB-crossing biomaterial platform for radiation-free molecular imaging of early-to-mid AD-associated Aβ pathology. STATEMENT OF SIGNIFICANCE: 1) Promising Targeting Strategy: We repurposed a human-derived natural receptor domain (LilrB2 D1D2) as a targeting module for β-amyloid (Aβ) oligomers, a key pathogenic species in Alzheimer's disease (AD). 2) Non-invasive MRI Approach: We constructed a liposomal probe designed to deliver the Gd-labeled targeting agent to the brain, enabling the detection of Aβ-associated pathology in 4-month-old 5xFAD mice via non-radioactive MRI, well before overt cognitive decline. 3) Experimental Validation: We demonstrate the probe's association with Aβ oligomers/plaques, effective BBB crossing, differences in MRI signals between AD model and wild-type mice, and an initially favorable biosafety profile, with no observed toxicity under the tested conditions. 4) Clinical Translation Potential: Our work presents a promising pathway toward a safe, accessible, and early-to-mid-stage AD screening tool, with the potential to facilitate population-wide screening and earlier therapeutic intervention. |
Acta biomaterialia | 2026 Oct 17 | PubMed |
| 07 |
Examining intersections of biographies & biologies: Diversity & outcomes of people with multiple sclerosis in Canada (iBio(2)Div-MS) protocol.
View abstractBACKGROUND: Although advances have been made in understanding multiple sclerosis (MS) disease etiology and developing new therapeutics, the benefits of these advances have been distributed inequitably across population groups. Persons with MS (PwMS) who are racialized, men, of lower social position, or living in rural areas experience worse outcomes for reasons yet to be fully elucidated. OBJECTIVE: We designed a prospective three-year longitudinal study to assess the individual and joint effects of contextual, biographical, and biological factors (e.g., sex, age, and genetics), on performance-based and patient-reported outcomes among groups under-represented in MS research. METHODS: We will enroll 500 PwMS and 100 individuals without MS who are aged ≥18 years, resident in Canada, able to complete interviews in English, commit to three years of participation, and self-identify as belonging to ≥1 of these groups: men, racialized, immigrant within the last ten years, 2SLGBTQI+, rural resident (population <10,000) or living with moderate-to-severe disability. Following e-consent, participants will provide a saliva sample for DNA collection and complete four telephone interviews over three years (at baseline and yearly thereafter). CONCLUSIONS: This study will provide insight into the joint contributions of contextual, biographical, and biological factors to health outcomes among underrepresented groups with MS. |
Multiple sclerosis and related disorders | 2026 Oct 15 | PubMed |
| 08 |
Baseline MRI markers and clinical outcomes during anti-amyloid β therapy: A real-world study in a Japanese dementia center.
View abstractIMPORTANCE: Predictors of decline and of amyloid-related imaging abnormalities (ARIA) during anti-amyloid β therapy in routine care are undefined. OBJECTIVE: To identify baseline predictors of cognitive, functional, and safety outcomes. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort of 161 consecutive patients initiating anti-amyloid β therapy at a Tokyo dementia center, 2024 to 2026 (lecanemab, 89; donanemab, 72). EXPOSURES: Lecanemab or donanemab. MAIN OUTCOMES AND MEASURES: Change in MMSE and CDR-Sum of Boxes (CDR-SB); baseline medial temporal atrophy (VSRAD Z score), amyloid PET burden, and microbleeds; ARIA. RESULTS: With lecanemab, MMSE and CDR-SB declined significantly at every assessment (CDR-SB +0.79, +1.10, +1.60 at 6, 12, 18 months); memory and orientation declined while language was preserved. Greater baseline medial temporal atrophy was associated with greater 12-month CDR-SB worsening (r = 0.39; P = .01; n = 40); patients in the most severe standard category (Z ≥ 3) worsened by 2.62 versus 0.64 points (adjusted β = +2.18; P < .001). Atrophy was associated with older age (r = 0.19; P = .03) and with baseline memory-related measures - ADAS-Cog score (r = 0.32; P < .001) and the MMSE subdomains of delayed recall (β = -0.25; P = .006) and time orientation (β = -0.30; P = .04) - but not MMSE total score. Amyloid PET burden showed no significant association at most time points. All ARIA events were asymptomatic; ARIA-H occurred in 6 of 25 with microbleeds versus 3 of 136 without (odds ratio, 14.0; P < .001). Donanemab follow-up was 6 months. CONCLUSIONS AND RELEVANCE: Baseline medial temporal atrophy was associated with functional decline and microbleeds with ARIA-H. Pretreatment MRI may provide prognostic and safety information during anti-amyloid β therapy. |
The journal of prevention of Alzheimer's disease | 2026 Oct 17 | PubMed |
| 09 |
Determinants of prescribers' recommendations of welfare technologies for people with dementia: a scoping review.
View abstractBACKGROUND: Welfare technologies are increasingly promoted to support people with dementia in living independently and safely. While prior research has primarily focused on user acceptance, usability, and effectiveness, less attention has been paid to the role of professionals who assess, select, and recommend these technologies. OBJECTIVE: This scoping review aims to identify and map the determinants that influence prescribers' recommendations of welfare technologies for people with dementia. METHODS: The review followed an established scoping review framework and adhered to PRISMA-ScR guidelines. Searches were conducted in Scopus, Web of Science, and PubMed, focusing on empirical studies published between 2016 and 2026. Studies were included if they examined professional practices related to recommending or prescribing welfare or assistive technologies for people with dementia. Sixteen studies met the inclusion criteria and were analysed using a descriptive thematic approach. RESULTS: Three categories of determinants were identified: professional, organisational and systemic, and technological and contextual. Professional determinants included knowledge, experience, ethical reasoning, and assessments of user and carer capability. Organisational determinants encompassed time constraints, training, procurement systems, and availability of technologies. Technological determinants related to usability, reliability, and suitability for cognitive impairment. Across studies, recommendation emerged as a sociotechnical process shaped by the alignment between these factors. CONCLUSIONS: The findings highlight that access to welfare technologies is mediated by professional recommendation practices and shaped by multi-level conditions. The study contributes a fit-based understanding of recommendation, emphasising the need to address professional, organisational, and technological conditions to improve equitable access to appropriate technologies in dementia care. |
Disability and rehabilitation. Assistive technology | 2026 Oct 17 | PubMed |
| 10 |
Intrinsic capacity impairments are associated with increased risk of incident dementia among community-dwelling older adults: Results from a 9-year follow-up of a nationwide cohort in Taiwan.
View abstractOBJECTIVES: The main aim of this study was to examine whether screening for intrinsic capacity (IC) impairments could identify those at increased risk of incidence of dementia among community-dwelling older adults. DESIGN: Nine-year longitudinal study. SETTINGS AND PARTICIPANTS: A total of 2308 community-dwelling persons aged 65 years or older who participated in the National Health Interview Survey (NHIS) in Taiwan, 2013. MEASUREMENTS: IC impairments were measured using the questionnaire from NHIS based on six domains of cognition, vitality, locomotion, vision, hearing, and psychological. The incidence of dementia was confirmed by the computerized data files of the Taiwan National Health Insurance claims database. RESULTS: In this study, a total of 358 persons developed incident dementia during the 9-year follow-up, giving a cumulative incidence rate of 15.5% (358/2308). Overall, 28.4% of participants had one IC domain impairment, 29.4% of participants had two or more domains impairment. Compared to those participants with no IC impairment, participants with one IC domain impairment had no increased risk of incident dementia (adjusted SHR=1.17; 95% CI=0.89-1.54), but increased risk was observed in participants with impairments in two or more domains (adjusted SHR=1.54; 95% CI=1.18-2.01). CONCLUSIONS: Our results highlight the high prevalence of participants with impairments in two or more IC domains and its independent association with increased risk of incident dementia among community-dwelling older adults. Further investigation is needed to explore whether such individuals could benefit from interventions to reduce risk of dementia. |
The Journal of frailty & aging | 2026 Oct 17 | PubMed |
| 11 |
miR‑660‑5p ameliorates neuronal damage in Alzheimer's disease via targeting APP.
View abstractAlzheimer's disease (AD) is a progressive neurodegenerative disorder of the central nervous system. To investigate miR‑660‑5p expression among patients with AD and explore the molecular mechanism underlying its regulation of AD‑related pathological progression. A total of 86 AD patients and 86 healthy controls were enrolled. Serum miR‑660‑5p was detected by real‑time quantitative PCR (RT-qPCR). Inflammatory factors were measured via enzyme‑linked immunosorbent assay (ELISA). SH‑SY5Y cells were treated with aggregated Aβ₁‑₄₂ preparation to establish an in‑vitro AD‑like injury model. Serum miR‑660‑5p was significantly downregulated in AD patients (P < 0.001), positively correlated with Mini‑Mental State Examination (MMSE, r = 0.684) and Montreal Cognitive Assessment (MoCA, r = 0.640) scores, and negatively correlated with serum interleukin‑6 (IL‑6, r = - 0.658) and tumor necrosis factor‑α (TNF‑α, r = - 0.614). Receiver‑operating characteristic (ROC) curve analysis for AD yielded an area under the curve (AUC) of 0.873. Mechanistically, miR‑660‑5p targets and inhibits APP expression to mitigate Aβ‑induced neuronal injury and neuroinflammation. miR-660-5p is downregulated in patients with AD. It mitigates aggregated Aβ₁-₄₂ preparation‑triggered neuronal damage and neuroinflammation in vitro by targeted inhibition of APP expression. |
Neurogenetics | 2026 Oct 17 | PubMed |
| 12 |
Improving the fairness and robustness of deep learning classification models through bias mitigation and post hoc calibration.
View abstractPURPOSE: The goal of this study was to enhance the fairness and clinical applicability of deep learning models for classifying Alzheimer's disease from structural MRI scans. To achieve this, we addressed two key challenges: age-related bias and unreliable probability estimates. Specifically, we investigated in-processing debiasing strategies to achieve age-invariant predictions while preserving diagnostic accuracy. We also systematically evaluated post hoc calibration methods to improve the reliability, interpretability, and clinical usefulness of predicted probabilities across diverse patient populations. METHODS: Structural MRI data from three independent cohorts (ADNI, AIBL, and DELCODE) were preprocessed using a standardized pipeline. Age-related bias was addressed using two in-processing strategies, adversarial training (CF-Net) and GLM-based feature residualization (PMDN), implemented in a shared 3D convolutional neural network (CNN) framework. Additionally, post hoc calibration was performed using four regression methods: logistic, probit, isotonic, and Bayesian binning. We evaluated model performance, fairness, and calibration using classification as well as calibration-specific metrics. RESULTS: PMDN achieved the best overall performance, with higher balanced accuracy (0.71) and improved calibration (Brier 0.22), showing substantially reduced variability compared to baseline and CF-Net. PMDN effectively removed age-related bias, achieving near-zero age prediction correlation; CF-Net, however, showed only partial and unstable debiasing. Post hoc calibration further improved probability reliability, with nonparametric methods (isotonic regression and Bayesian binning) yielding the lowest calibration errors (MCE 0.21-0.24). CONCLUSION: This study shows that, although deep learning models achieve similar classification performance, they differ significantly in terms of calibration, stability, and fairness. PMDN provides more consistent and effective age bias mitigation than the CF-Net approach, particularly in clinically relevant subgroups. Post hoc calibration improves probability reliability further, with nonparametric methods achieving the best calibration. |
International journal of computer assisted radiology and surgery | 2026 Oct 17 | PubMed |
| 13 |
A Review of the Molecular Evidence for Near-Infrared Light in Astrocyte-Mediated Neurorehabilitation.
View abstractNear-infrared (NIR) light represents a promising, noninvasive therapeutic for neurological disorders, predicated on its capacity to modulate astrocyte function. As the primary glial population in the central nervous system, astrocytes are indispensable for maintaining neuronal homeostasis, regulating glutamate metabolism, and supporting metabolic energetics. This review synthesizes recent advancements in NIR-driven neurorehabilitation, elucidating the molecular signaling cascades and transduction pathways activated within the astrocytic network. We specifically examine translational applications across preclinical and clinical models of stroke, Alzheimer's disease, epilepsy, and psychiatric disorders. Furthermore, we evaluate how the integration of optogenetic tools and nanomaterials has refined NIR therapies, establishing a foundation for high-precision neurology. Given the rising demand for nonsurgical interventions, this review provides a timely framework for the next generation of photobiomodulation and neural modulation strategies. |
Molecular neurobiology | 2026 Oct 17 | PubMed |
| 14 |
Neuroprotective Role of Withaferin A in Huntington's Disease: Current Evidence and Future Perspectives.
View abstractHuntington's disease (HD) is an inherited neurodegenerative disorder caused by an expanded CAG repeat in the huntingtin (HTT) gene. Its pathogenesis involves mutant huntingtin aggregation, impaired proteostasis and autophagy, transcriptional dysregulation, mitochondrial dysfunction, oxidative stress, neuroinflammation and progressive neuronal loss. Withaferin A (WA), a steroidal lactone derived from Withania somnifera, has demonstrated antioxidant, anti-inflammatory, proteostasis-modulating and stress-response effects in experimental studies. In a transgenic HD mouse model, WA-induced heat-shock-response activation was associated with reduced mutant huntingtin aggregation and attenuation of selected disease-related abnormalities. In contrast, evidence for nuclear factor erythroid 2-related factor 2/antioxidant response element (Nrf2/ARE) activation, autophagy regulation, mitochondrial protection and suppression of inflammatory signaling is derived predominantly from cellular experiments and non-HD neurological or inflammatory models rather than from validated HD models. The direct relevance of these proposed mechanisms to HD therefore remains to be established. No clinical studies have demonstrated the safety or therapeutic efficacy of WA in individuals with HD. Moreover, its bioavailability, pharmacokinetic behavior, optimal dose, long-term toxicity, central nervous system exposure and possible drug interactions remain insufficiently characterized. This review critically evaluates HD-specific and indirect evidence concerning the neuroprotective actions of WA, identifies important methodological and translational limitations and discusses priorities for future investigation. Current evidence supports WA as an experimental compound for further preclinical study rather than as an established or clinically applicable treatment for HD. |
Molecular neurobiology | 2026 Oct 17 | PubMed |
| 15 |
Patterns of Stakeholder Participation in Advance Care Planning for Older Adults With Alzheimer's Disease in China: A Cross-Sectional Study.
View abstractAIMS: To examine advance care planning (ACP) participation among older adults with Alzheimer's disease (AD), their family caregivers, and healthcare professionals in China, and to identify key influencing factors and challenges from a stakeholder perspective. DESIGN: A cross-sectional survey guided by stakeholder theory. The study was reported in accordance with the The STROBE checklist. METHODS: A cross-sectional study was conducted from December 2024 to July 2025 in two tertiary hospitals and one social welfare center in Hangzhou, China. Convenience sampling was used to recruit healthcare professionals, older adults with early-stage AD, and family caregivers of AD patients. Structured questionnaires assessed ACP preparedness or participation. Data were analysed using descriptive statistics, correlation analyses, and multiple linear regression. RESULTS: Healthcare professionals demonstrated high ACP knowledge and positive attitudes but low engagement in ACP-related behaviours. Older adults with early-stage AD showed moderate ACP preparedness, characterized by strong beliefs and motivation but relatively low attitudinal readiness. Family caregivers reported moderate-to-high ACP participation while experiencing substantial decision conflict. Stakeholder theory was used to interpret group differences in ACP preparedness, participation, and decision conflict. The findings reflect inherent disparities in decision-making power, accessible resources, and interest demands among patients, family caregivers, and healthcare professionals. CONCLUSIONS: ACP participation in Chinese families affected by AD remains fragmented and structurally constrained. Although stakeholders recognize ACP's value, disparities in roles, resources, and power hinder patient-centered decision-making. IMPLICATIONS FOR CLINICAL PRACTICE: This study provides references for the clinical implementation of Advance Care Planning (ACP) for dementia patients, the construction of multidisciplinary collaboration models, and the development of caregiver support strategies in the Chinese cultural context. PATIENT AND PUBLIC CONTRIBUTION: Healthcare professionals, patients, and family members participated in data collection, providing comprehensive empirical evidence on ACP-related attitudes, behaviours, and decision conflicts for the study. |
Journal of clinical nursing | 2026 Oct 17 | PubMed |
| 16 |
SURVEY BEHAVIOR AND COGNITION ACROSS THE LIFE COURSE: EVIDENCE FROM THE PANEL STUDY OF INCOME DYNAMICS.
View abstractCognitive abilities across adulthood are important pre-cursors to dementia. The primary way to capture cognitive abilities is via expensive and time-consuming standardized cognitive tests. We explore the extent to which cognition can be inferred from indicators of survey response behavior (SRB), such as the time to complete a questionnaire and the incidence of contradictory responses. We use nationally representative data from a mixed-mode supplement to the Panel Study of Income Dynamics collected in 2016. This Wellbeing and Daily Life supplement includes rich cognitive data capturing both verbal and quantitative reasoning, and paradata from the supplement (e.g., time to complete). We assess the ability of survey response behavior to improve prediction of cognitive ability after accounting for standard sociodemographic variables typically available in surveys. We explore this from age 30 and across the life course. We find that SRB measures provide modest but consistent explanatory power across a wide range of ages. The explanatory power of SRB measures in our data is less than that of education, except at the oldest ages. SRB measures contain useful additional information, but models that include basic demographics, education and SRB measures leave much of the variation in cognitive ability unexplained. Which SRB measures best predict cognitive ability is consistent across cognitive measure but differs by age. Errors (i.e., contradictory responses) and response times are the best predictors at working ages but skips and backups are more predictive at older ages. |
Journal of survey statistics and methodology | 2026 Oct 15 | PubMed |
| 17 |
Potentially Clinically Relevant Drug-Drug Interactions with Direct Oral Anticoagulants: Prevalence and Contributing Factors.
View abstractBACKGROUND: Direct oral anticoagulants (DOACs) are widely prescribed but remain susceptible to drug-drug interactions (DDIs) that increase bleeding or thrombotic risk. The real-world prevalence and factors associated with potentially clinically relevant DDIs in patients on chronic DOAC therapy require further study. OBJECTIVE: To determine the prevalence of clinically relevant DDIs involving DOACs and identify patient- and treatment-related factors associated with their occurrence. METHODS: A retrospective cross-sectional study was conducted among hospitalized adults receiving a DOAC as a home medication. Potentially clinically relevant DDIs were identified from documented home medications using the Lexicomp Online 2025 Drug Interactions database and classified as category C (monitor therapy), D (consider modification), and X (avoid combination). Clinical bleeding, thromboembolic, or other adverse outcomes were not assessed. Descriptive statistics and multivariable logistic regression analyzed patient characteristics and factors associated with DDIs. RESULTS: Among 870 patients (mean age 71.4 ± 13.0 years), 72.8% had at least one potentially clinically relevant DDI. Among patients with at least one potentially clinically relevant DDI, 47.4% had multiple interactions. Most were Category C (97.6%), primarily involving antidepressants with antiplatelet activity (30.4%), antiplatelet agents (30.0%), amiodarone (8.5%), and NSAIDs (7.9%). Category D and X interactions (2.4%) mainly involved CYP3A4/P-gp inhibitors or inducers such as dronedarone, erythromycin, and phenytoin. Independent predictors of DDI occurrence included the number of medications (OR 1.14; 95% CI 1.09-1.19; p < 0.0001), coronary artery disease (OR 1.55; p = 0.039), anxiety (OR 2.02; p = 0.016), dementia (OR 2.99; p = 0.006), and depression (OR 3.27; p = 0.001). CONCLUSION: Potentially clinically relevant DDIs involving DOACs were common in this hospitalized cohort, although most identified interactions were Category C and therefore primarily warranted monitoring. Higher medication burden and several comorbidities, including coronary artery disease, depression, anxiety and dementia were associated with the presence of potentially clinically relevant DDIs. Vigilant medication review is essential to enhance safety. |
Drug, healthcare and patient safety | 2026 | PubMed |
| 18 |
Development and validation of predictive models for undiagnosed Alzheimer's disease and related dementias in the emergency department.
View abstractINTRODUCTION: The electronic health record (EHR) offers a promising resource to improve recognition of Alzheimer's disease and related dementias (ADRD), yet existing approaches have been developed within cohorts that underrepresent individuals prone to underdiagnosis and do not differentiate disease severity. METHODS: We applied a validated computational phenotype to identify probable ADRD (p-ADRD) and its severity within a random sample of 5000 individuals aged ≥65 years who presented to one of nine emergency departments in the Yale New Haven Health System (2014 to 2022). The dichotomous outcome was undiagnosed ADRD, assigned to those meeting criteria for p-ADRD but lacking validated diagnostic codes. We applied logistic regression with elastic net regularization to predict undiagnosed status for the overall cohort and within each severity stratum, assessing performance using 10-fold cross-validation. RESULTS: Of 1358 individuals with p-ADRD (mean age 86.7 years, standard deviation 7.4), 934 (68.8%) were undiagnosed. The overall model discriminated undiagnosed ADRD with an area under the receiver operating characteristic curve (AUROC) of 0.85 (95% confidence interval [CI] 0.83 to 0.87). The severity-stratified models achieved AUROC of 0.80 (95% CI 0.77 to 0.83) for mild and 0.91 (95% CI 0.88 to 0.94) for moderate to severe disease. Although the predictors of undiagnosed status differed by severity, fall-related injury was protective against underdiagnosis within each stratum. DISCUSSION: We developed and validated predictive models using structured EHR elements, which demonstrated robust discrimination of undiagnosed ADRD within a clinical cohort prone to underdiagnosis. The heterogeneous predictors across severity strata underscore the importance of aligning prediction with disease severity, given the distinct clinical needs that attend ADRD progression. |
Alzheimer's & dementia (Amsterdam, Netherlands) | 2026 Oct-Dec | PubMed |
| 19 |
GLP-1 receptor agonists in Alzheimer's disease and MCI: a meta-analysis.
View abstractINTRODUCTION: Alzheimer's disease (AD) is the leading cause of dementia in older individuals and remains a major clinical and socioeconomic burden. Despite the success of anti-amyloid therapies in reducing biomarker burden, more effective and safer treatments are still needed. Given the emerging evidence of a role for metabolic dysfunction and brain insulin resistance in AD pathophysiology, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been proposed as potential disease-modifying therapies. METHODS: We conducted a systematic review and meta-analysis of PubMed, Embase, CENTRAL, and ClinicalTrials.gov from inception to April 22, 2026 to evaluate the efficacy and safety of GLP-1 RAs in AD and mild cognitive impairment. Randomized controlled trials comparing GLP-1 RAs with placebo, standard care, or non-intervention across the Alzheimer's continuum were eligible; abstracts and studies with unavailable results were excluded. Random-effects models were used. Risk ratios (RRs) were calculated for binary outcomes, and mean or standardized mean differences for continuous outcomes. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. RESULTS: Seven studies comprising 4132 participants met the inclusion criteria. The mean age of the pooled studies was 72.1 years, while the mean baseline Clinical Dementia Rating-Sum of Boxes (CDR-SB) varied from 2.71 to 3.8. GLP-1 RAs were not associated with significant improvement in cognition (Alzheimer's Disease Assessment Scale-Cognitive Subscale: standard mean difference -0.05; 95% confidence interval [CI]: -0.12 to 0.02; = 0.1928) or disease progression (CDR-SB: mean difference: 0.09; 95% CI: -0.10 to 0.28; = 0.362). They were associated with a higher frequency of adverse events (RR 1.07; 95% CI: 1.04 to 1.10; < 0.0001) and weight loss (RR 5.01; 95% CI: 3.99 to 6.27; < 0.0001). Biomarker and neuroimaging findings were inconsistent and failed to translate to clinical benefit. DISCUSSION: GLP-1 RAs did not improve cognitive or functional outcomes in AD and were associated with adverse events. Their role may be better explored in biomarker-enriched, metabolically selected populations or assessment of GLP-1 RAs with greater brain penetrance. |
Alzheimer's & dementia (New York, N. Y.) | 2026 Oct-Dec | PubMed |
| 20 |
Lactate-Informed Exercise Prescription in Mild Cognitive Impairment and Alzheimer's Disease: A Translational Framework for Preserving Cognition, Mobility, and Independence.
View abstractBACKGROUND: This narrative review proposes a conceptual, lactate-informed framework for individualized exercise prescription in mild cognitive impairment (MCI) and Alzheimer's disease (AD). Exercise is recommended in these populations, but fixed external doses do not account for heterogeneity in disease stage, frailty, sarcopenia, cardiovascular risk, or recovery. MAIN TEXT: We integrate clinical exercise evidence, geriatric assessment, lactate physiology, muscle-brain signaling, implementation science, and trial methodology. The framework uses peripheral blood lactate as one component of a monitoring matrix with workload, heart rate, blood pressure, perceived exertion, fatigue recovery, gait safety, adherence, and caregiver support. Repeated, standardized lactate responses are classified as low, adaptive and recoverable, excessive, or non-interpretable/unsafe, prompting stepwise adjustment of aerobic, resistance, balance, and cognitive-motor training. Peripheral blood lactate is an internal-load marker; it does not directly quantify blood-brain barrier transport, CNS lactate kinetics, or target engagement. Mechanistic pathways involving monocarboxylate transport, HCAR1, BDNF/VEGF, myokines, and lactylation therefore remain hypotheses to be tested in humans with MCI or AD. CONCLUSIONS: The novelty of the framework is its integration of disease stage, geriatric phenotype, peripheral metabolic response, and recovery into clinically actionable dose decisions rather than a universal lactate threshold. Prospective multicenter trials should standardize sampling, validate response thresholds, and determine whether this approach improves cognition, mobility, independence, safety, and caregiver-relevant outcomes beyond usual advice or fixed-dose exercise. |
Clinical interventions in aging | 2026 | PubMed |
| 21 |
Integration of blood-based biomarkers and genomic variants identifies individuals with mild cognitive impairment who benefit from multidomain intervention.
View abstractINTRODUCTION: Our recent Japan-Multimodal Intervention Trial for the Prevention of Dementia (J-MINT) trial suggested that multidomain lifestyle interventions may delay cognitive decline. However, substantial interindividual variability in response persists, and identifying individuals more likely to benefit from the intervention remains challenging. Blood-based biomarkers (BBMs), which provide a minimally invasive means of assessing Alzheimer's disease (AD)-related pathological processes, may help identify biologically distinct subgroups of individuals with mild cognitive impairment (MCI). METHODS: Blood-based biomarkers-including amyloid-β42/40 ratio, phosphorylated tau-217, neurofilament light chain, and glial fibrillary acidic protein (GFAP)-were measured in J-MINT participants. Hierarchical clustering based on BBM profiles was used to identify biologically defined subgroups. Whole-genome sequencing data were analyzed using genome-wide association analysis (GWAS) to identify genetic variants associated with the BBM-based subgroup. A prediction model for the subgroup assignment was constructed using the associated incorporating the genetic variants, age, sex, and apolipoprotein E4 ( allele count. Model performance was evaluated using five-fold cross-validation repeated 1000 times. RESULTS: BBM-based clustering identified a subgroup characterized by elevated GFAP and multiple biomarker abnormalities. Within this subgroup, the change in cognitive performance from baseline to 18 months differed significantly between intervention and control groups, with greater decline observed in the control group. GWAS identified four variants showing suggestive association with the subgroup, two of which were located in intronic regions of genes associated with hearing loss ( and ). DISCUSSION: BBM-based clustering identified biologically distinct subgroups among individuals with MCI. The subgroup characterized by multiple biomarker abnormalities and elevated GFAP showed differential cognitive trajectories between the intervention and control groups. These findings suggest that BBMs, potentially in combination with genetic information, may help identify individuals with a more progressive AD-related biological profile who may derive greater benefit from multidomain intervention. |
Alzheimer's & dementia (New York, N. Y.) | 2026 Oct-Dec | PubMed |
| 22 |
Neuroprotective Effects of Food-Derived Cyanidin Glycosides in an Alzheimer's Disease-Like Zebrafish Model Through Modulation of PI3K/Akt/GSK3β Signaling.
View abstractAlzheimer's disease (AD) is a progressive neurodegenerative disorder lacking effective and safe interventions. Food-derived anthocyanins have gained increasing attention due to their neuroprotective potential; however, the specific mechanisms of individual cyanidin glycosides remain insufficiently understood. Notably, the comparative efficacy and mechanistic differences among structurally distinct cyanidin glycosides have not been systematically evaluated in vivo. In the present study, three cyanidin glycosides, cyanidin-3--rutinoside (C3R), cyanidin-3--sophoroside (C3S), and cyanidin-3--xyloside (C3X), were evaluated using an aluminum chloride (AlCl)-induced zebrafish model of AD-like pathology. The results showed that these compounds improved cognitive performance and anxiety-like behavior, while attenuating oxidative stress and neuroinflammation and restoring cholinergic function, as evidenced by biochemical and immunofluorescence analyses. In addition, neuronal damage and Tau phosphorylation at Ser396 were markedly alleviated. Among the tested compounds, C3R consistently exhibited the most pronounced effects across multiple indicators. Mechanistically, the three cyanidin glycosides modulated PI3K/Akt/GSK3β signaling, as reflected by overall increases in p-PI3K (Tyr458)/PI3K and p-Akt (Ser473)/Akt and decreases in p-GSK3β (Tyr216)/GSK3β and p-Tau (Ser396)/Tau. LY294002 attenuated the pathway-associated protective effects, supporting the involvement of PI3K/Akt signaling. Collectively, these findings demonstrate neuroprotective effects associated with modulation of PI3K/Akt/GSK3β signaling, with C3R showing the strongest overall efficacy. |
Food science & nutrition | 2026 Oct | PubMed |
| 23 |
Digital patient-reported outcomes to evaluate treatment response to filgotinib in patients with ulcerative colitis.
View abstractOBJECTIVE: Patient-reported outcomes (PROs) are valuable tools for improving long-term patient outcomes and providing patient-centered care. PROs can be used to investigate real-world treatment effectiveness in patients with a chronic inflammatory disease. METHODS: This was a real-world cohort study with digital patient-reported data collection by patients with ulcerative colitis (UC) using TrueColours-IBD, a web-based platform for prospective monitoring of symptoms, quality of life, and outcomes in Oxford. Effectiveness of filgotinib was compared between advanced therapy-naïve (ATN, i.e. filgotinib 1st line, = 44) and advanced therapy-experienced (ATE, i.e. prior biological/small-molecule therapy, = 56) patients using the following outcomes, evaluated post-induction (8-12 weeks) and at 6 and 12 months: clinical remission (Simple Clinical Colitis Activity Index (SCCAI) ≤2), clinical response (≥2 point SCCAI reduction from baseline), corticosteroid-free remission (defined as clinical remission without any prednisolone or budesonide in the 12 weeks preceding that time point), and treatment discontinuation (defined as stopped prescription of the medication). RESULTS: There were no significant differences between the ATN and ATE groups regarding clinical remission, response, and corticosteroid-free remission at any time point, with values > 0.1. More than half of the patients in each group achieved clinical remission and response at all time points. Filgotinib discontinuation rates within 12 months were comparable ( = 0.095). CONCLUSION: This study shows that PROs can serve as an important tool in evaluating real-world treatment outcomes in patients with UC using filgotinib. The results demonstrate good subjective clinical effectiveness, regardless of prior advanced therapy exposure. |
Patient related outcome measures | 2026 | PubMed |
| 24 |
Lecanemab-Monoclonal Antibodies for the Treatment of Early Alzheimer's Disease.
View abstractOBJECTIVE: Review the pharmacology, efficacy, and safety of lecanemab, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody, for the treatment of early Alzheimer's disease (AD). DATA SOURCES: Comprehensive search of Embase, PubMed, International Pharmaceutical Abstracts, Cochrane CENTRAL, Scopus, Web of Science, and Google Scholar were conducted from inception through December 2025. STUDY SELECTION AND DATA EXTRACTION: Phase I-III clinical trials, systematic reviews, and meta-analyses evaluating lecanemab pharmacology, pharmacokinetics, efficacy, and safety were included. Product labeling was reviewed to supplement clinical data. DATA SYNTHESIS: In the phase III Clarity AD trial, patients were randomized 1:1 to lecanemab 10 mg/kg every 2 weeks or placebo. The primary endpoint was change from baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) score at 18 months. Lecanemab demonstrated a mean change of 1.21 versus 1.66 with placebo (difference, -0.45; 95% CI, -0.67 to -0.23; < .001). Secondary endpoint, amyloid burden via positron emission tomography (PET) scans ( = 698) showed -55.48 centiloids with lecanemab versus 3.64 with placebo (difference -59.12 centiloids; 95% CI, -62.64 to -55.6; < .001). Additional endpoints included changes in ADAS-cog 14, ADCOMS, and ADCS-MCI-ADL scores favoring lecanemab over placebo. Lecanemab was well tolerated; infusion site reactions occurred in 26.4%. Amyloid-related imaging abnormalities (ARIA-E) occurred in 12.6% of participants. CONCLUSION: Compared to placebo, lecanemab demonstrated statistically significant slowing of cognitive decline on CDR-SB and secondary endpoints, including amyloid burden reduction. However, its clinical benefit must be weighed against ARIA risk and substantial financial burden. Current evidence supports its use in carefully selected patients with early AD under close supervision. |
The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians | 2026 Oct 14 | PubMed |
| 25 |
Network pharmacology-driven identification of PTP1β and rational design of simufilam-based allosteric inhibitors for neuroprotection in Alzheimer's disease.
View abstractUNLABELLED: Alzheimer's disease (AD) is a progressive neurodegenerative disorder that predominantly affects elderly people and is characterized by cognitive decline and dementia. Protein tyrosine phosphatase-1B (PTP1B) is known to modulate pro-inflammatory mediators, and its overexpression in the brain has been implicated in AD-associated neuroinflammation. This study explores the mechanism of A20, A26, and co-crystal-designed compound targeting non-competitive allosteric PTP1B enzyme inhibition for AD therapy using network pharmacology and computational studies. Protein-protein interaction was designed for 128 active targets by STRING database and Cytoscape software. Further, active target-associated pathways analysed using ClueGO plugin Cytoscape software and the Reactome online public domain server. The non-competitive allosteric PTP1B inhibition through the design of Simufilam derivatives, with particular emphasis on A20, which is predicted to bind at the non-competitive allosteric site of the PTP1B protein (PDB ID: 1T49), involves α3, α6, and α7 helices that influence the WPD loop orientation. The proposed non-competitive allosteric binding mode is based on computational evidence and for that further experimental validation would be required to conclusively confirm binding of the designed compounds within this regulatory region. Using in-silico approaches, including molecular docking, identified A20 with the most favourable predicted binding energy score (-10.8 kcal/mol) compared to other derivatives. Molecular dynamics simulations further indicated structural stability of the PTP1B-A20, 26, and co-crystal complex, with consistent RMSD, RMSF, H-bond, Rg, and SASA. Principal component analysis suggested that A20 restricts conformational flexibility; hence MM-PBSA analysis displayed its stable binding free energies. Density functional theory (DFT) calculation characterized the polarity, stability, and reactivity of A20 studies supported its favourable electronic configuration. Overall, A20 displayed superior calculated binding energies, trajectory stability, and predicted drug-likeness, positioning it as a promising lead candidate for future empirical validation in AD research. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at https://doi.org/10.1007/s13205-026-05086-2. |
3 Biotech | 2026 Nov | PubMed |

